🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Chengdu
Clinical trial register · China

Clinical Trials in Chengdu, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Beijing 5484 Shanghai 3827 Guangzhou 3318 Hangzhou 1812 Wuhan 1343
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
West China Hospital162 AstraZeneca148 Janssen Research & Development, LLC55 Hoffmann-La Roche44 Sichuan University44
Site location
Beijing5484 Shanghai3827 Guangzhou3318 Hangzhou1812 Wuhan1343
All 613 locations
Target enrolment
to

Trials with a site in Chengdu

1291 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Recruiting
PULSAR Combined With Fecal Microbiota Transplantation for Advanced Hepatocellular Carcinoma Progressing After First-Line Targeted-Immunotherapy
NCT07463248Hepatocellular Carcinoma (HCC)
Wang Xin
Phase 2
64
Chengdu
2026-04-15
Recruiting
Assessing Treatment of T-Cell Lymphoma With GW5282 in Combination With Golidocitinib (BEI-DOU3)
NCT07496229T-cell Lymphomas
Dizal Pharmaceuticals
Phase 1/2
165
Chongqing, Fuzhou, Nanning, Zhengzhou, Wuhan, Nanjing, Chengdu, Taizhou
2026-04-15
Recruiting
A Study of Zovaglutide (ZT002 Injection) in Participants With Impaired Kidney Function and Healthy Participants
NCT07443059Overweight , Obesity
Beijing QL Biopharmaceutical Co.,Ltd
Phase 1
40
Xiamen, Jinan, Chengdu
2026-04-13
Recruiting
DAREON ® -Lung-1: A Study in People With Advanced Small Cell Lung Cancer to Compare Obrixtamig Plus Atezolizumab, Carboplatin, and Etoposide Treatment With Standard Chemoimmunotherapy
NCT07472517Small Cell Lung Cancer (SCLC), Extensive-stage Small Cell Lung Cancer (ES-SCLC)
Boehringer Ingelheim
Phase 3
670
Beijing, Bengbu, Changsha, Chengdu, Fuzhou, Guangzhou, Hangzhou, Harbin
2026-04-13
Recruiting
BALANCE Trial Domain Within the ACT-GLOBAL Adaptive Platform Trial-NCT06352632
NCT07318948Acute Ischemic Stroke
Bo Wu
Not applicable
1,600
Chengdu
2026-04-09
Recruiting
A Clinical Study of SHR-4394 in Combination With Anti-tumor Therapy in Prostate Cancer
NCT07407283Prostate Cancer
Jiangsu HengRui Medicine Co., Ltd.
Phase 1/2
100
Chengdu, Tianjin
2026-04-08
Not yet open
Effect of AI Critical Appraisal Training on Critical Thinking in Nursing Students
NCT07538986Healthy
Xi Cao
Not applicable
400
Chengdu
2026-04-07
Recruiting
MDT-Based Umbrella Decision Model for Geriatric Lung Cancer Patients
NCT07509333Lung Neoplasms, Carcinoma, Non-Small-Cell Lung, Small Cell Lung Carcinoma
West China Hospital
Not applicable
2,000
Chengdu
2026-04-05
Recruiting
Grid eXplore Mapping Study
NCT07421076Paroxysmal Atrial Fibrillation (PAF)
Abbott Medical Devices
Not applicable
200
Jinan, Chengdu, Hangzhou, Ningbo, Beijing
2026-04-02
Not yet open
The Comparison Between M-E-BCS and C-O-BCS.
NCT07539545Breast Cancer
Du Zhenggui
Not applicable
1,366
Chengdu
2026-04-01
Recruiting
Effect of NOTCH2NLC Gene Variations on NIID Clinical Features
NCT07670169Neuronal Intranuclear Inclusion Disease (NIID)
Sichuan Academy of Medical Sciences
Observational
12
Chengdu
2026-04-01
Recruiting
GV20-0251 and Sintilimab for Neoadjuvant Treatment of Resectable Head and Neck Squamous Cell Carcinoma: A Single-Arm Study
NCT07457281Head and Neck Squamous Cell Carcinoma HNSCC
West China Hospital
Phase 1
9
Chengdu
2026-04-01
Not yet open
Safety and Efficacy of LVD + C-TACE + Tis/Len for Unresectable Right-Liver HCC
NCT07480382Initially Unresectable Hepatocellular Carcinoma
Hong Wu
Not applicable
30
Chengdu
2026-04-01
Recruiting
A Study of Enpatoran in Participants With Cutaneous Manifestations of Lupus With or Without Systemic Disease (ELOWEN-2)
NCT07355218Systematic Lupus Erythematosus, Cutaneous Lupus Erythematosus
EMD Serono Research & Development Institute, Inc.
Phase 3
202
Shijiazhuang, Luoyang, Nanjing, Jinan, Chengdu
2026-04-01
Recruiting
Osimertinib Induction and Maintenance for Chemo-ineligible Stage III Unresectable EGFR+ NSCLC: Single-arm Study
NCT07295821Lung Cancer
AstraZeneca
Phase 2
60
Beijing, Changchun, Changsha, Chengdu, Foshan, Fuzhou, Guangzhou, Harbin
2026-04-01
Recruiting
NALIRIFOX+Adebrelimab+PULSAR for Advanced Pancreatic Cancer
NCT07595172Pancreatic Ductal Adenocarcinoma (PDAC), Locally Advanced and Metastatic Pancreatic Cancer
West China Hospital
Phase 1/2
55
Chengdu
2026-04
Recruiting
Intensive Nutritional Support in Conversion Therapy for Locally Advanced Unresectable ESCC
NCT07519486Esophageal Squamous Cell Carcinoma, Locally Advanced Unresectable Esophageal Squamous Cell Carcinoma
Sichuan University
Phase 2
118
Chengdu
2026-04
Not yet open
Efficacy of a Toothpaste in Reducing Plaque, Gingivitis, and Gingival Bleeding
NCT07499115Plaque, Dental, Gingivitis
Colgate Palmolive
Phase 3
90
Chengdu
2026-04
Recruiting
Traditional Chinese Medicine Preparation Alleviates Radiotherapy-induced Oral Mucositis in Head and Neck Cancer Patients.
NCT07339774Radiotherapy-induced Oral Mucositis
West China Hospital
Phase 2
128
Chengdu
2026-03-30
Recruiting
Can Perineal Post-Free Traction in Hip Arthroscopy Effectively Reduce Perineal Complications?
NCT07322705Femoroacetabular Impingement Syndrome
ChunBao Li
Not applicable
270
Beijing, Shenzhen, Luoyang, Nanjing, Xi'an, Tai’an, Shanghai, Chengdu
2026-03-30
Not yet open
Nano-Carbon Iron Suspension Injection Combined With Radiotherapy for Solid Tumors Phase II Clinical Trial
NCT07491783HNSCC, Soft Tissue Cancer
Sichuan Enray Pharmaceutical Sciences Company
Phase 2
52
Chengdu
2026-03-27
Recruiting
A Study of HRS-6208 in Combination With HRS-8080, or Fulvestrant, or Letrozole, With or Without HRS-6209 in Patients With Advanced Unresectable or Metastatic Breast Cancer
NCT07389733Advanced Unresectable or Metastatic Breast Cancer of Adults
Shandong Suncadia Medicine Co., Ltd.
Phase 1/2
180
Dalian, Chengdu
2026-03-27
Recruiting
A Study on Recombinant Botulinum Toxin Type A (YY001) for Injection in Multiple Treatments of Adult Upper Limb Spasticity
NCT07478822Upper Limb Spasticity
Chongqing Claruvis Pharmaceutical Co., Ltd.
Phase 3
300
Beijing, Chengdu, Guangdong, Guangzhou, Hefei, Huai'an, Kaifeng, Kunming
2026-03-27
Recruiting
Intratumoral Injection of Recombinant Human Endostatin Adenovirus (EDS01) for the Treatment of Recurrent or Metastatic Head and Neck Tumors
NCT07625423Head & Neck Cancer, Nasopharyngeal Cancinoma (NPC)
West China Hospital
Phase 1
9
Chengdu
2026-03-27
Recruiting
LY4268989 in Adults With Moderately to Severely Active Ulcerative Colitis
NCT07415044Ulcerative Colitis (UC), Ulcerative Colitis, Active Moderate, Ulcerative Colitis, Active Severe
Eli Lilly and Company
Phase 2
1,431
Binzhou, Changzhou, Chengdu, Chongqing, Foshan, Guangzhou, Harbin, Hefei
2026-03-26
Not yet open
Efficacy and Safety of Intra-arterial Tenecteplase in Acute Ischemic Stroke Patients With Medium Vessel Occlusion Stroke (DATE-MeVO)
NCT07469293Acute Ischemic Stroke
Southwest Hospital, China
Phase 3
488
Baise City, Guilin, Qiannan, Chengdu, Dali, Qujing, Ankang, Anyang
2026-03-25
Recruiting
A Study of BL-M24D1 in Patients With Relapsed or Refractory Multiple Myeloma and Other Hematologic Malignancies
NCT07255898Multiple Myeloma, Hematologic Malignancies
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 1
33
Chengdu
2026-03-25
Recruiting
A Study to Investigate the Efficacy, Safety and Tolerability of Votoplam in Participants With Huntington's Disease
NCT07326709Huntington Disease
Novartis Pharmaceuticals
Phase 3
770
Guangzhou, Wuhan, Changsha, Chengdu, Hangzhou
2026-03-24
Recruiting
PODOMOUNT-Basket, a Study to Test Whether BI 764198 Helps Adults and Adolescents With Different Types of Kidney Disease
NCT07355296Proteinuric Kidney Diseases
Boehringer Ingelheim
Phase 2
132
Beijing, Chengdu, Guangzhou, Nanchang, Nanjing, Nanning, Shanghai, Sichuan
2026-03-23
Recruiting
Trunk Inclination, Positive End-expiratory Pressure, and Lung Recruitability
NCT07504731Acute Respiratory Distress Syndrome (ARDS)
Zhongda Hospital
Observational
40
Nanjing, Jinan, Chengdu
2026-03-20
Recruiting
A Phase III Study of HMPL-760 Plus R-GemOx VS Placebo Plus R-GemOx in Relapsed/Refractory DLBCL
NCT07409428Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Hutchmed
Phase 3
240
Shanghai, Baoding, Beijing, Bengbu, Changchun, Changsha, Chengdu, Chongqing
2026-03-20
Recruiting
Radiotherapy After Prostatectomy for Node Positive Prostate Cancer
NCT07477626Prostate Cancer (Post Prostatectomy), Radiotherapy; Image-Guided, Prostate Cancer Non-Metastatic, Androgen Deprivation Therapy
Sun Yat-sen University
Phase 3
372
Dongguan, Guangzhou, Zhanjiang, Zhengzhou, Chengdu, Hangzhou, Beijing, Shanghai
2026-03-20
Recruiting
A Study to Investigate the Clinical Outcome and Quality of Life in Chinese Post-operative CRSwNP Patients
NCT07446738Chronic Rhinosinusitis With Nasal Polyps
AstraZeneca
Observational
200
Changchun, Changsha, Chengdu, Guangzhou, Haikou, Kunming, Nanchang, Nanjing
2026-03-19
Recruiting
A Clinical Trial of Flonoltinib Maleate Tablets in the Treatment of JAK Inhibitor Refractory/Relapsed/Intolerant Patients With Intermediate to High Risk Myelofibrosis
NCT07443306MF
Chengdu Zenitar Biomedical Technology Co., Ltd
Phase 2
64
Chengdu, Tianjin
2026-03-18
Recruiting
A Study of MG2512 Injection in Participants With Advanced Solid Tumors
NCT07348653Advanced Solid Tumor
Shanghai Mabgen Biopharmaceutical Technology Co., Ltd.
Phase 1
116
Beijing, Chengdu
2026-03-18
Recruiting
Helium-free Magnetocardiography Guided Therapy for Stable Coronary Artery Disease - A Randomized Controlled Trial
NCT07341932Stable Coronary Artery Disease CAD
Beijing Anzhen Hospital
Not applicable
1,312
Beijing, Chengdu, Ürümqi
2026-03-17
Recruiting
A Phase I Study of Single Subcutaneous Dose of SHR-1894 in Healthy Subjects
NCT07414602Dermatitis
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Phase 1
40
Chengdu
2026-03-16
Recruiting
Traditional Chinese Medicine Oral Liquids and Mouthwashes for Radiation-induced Oral Mucositis in Head and Neck Cancer Patients
NCT07282483Radiation-induced Oral Mucositis
West China Hospital
Phase 2
118
Chengdu
2026-03-16
Recruiting
Development and Application of a Nurse-Led Preemptive Symptom Management Protocol for Head and Neck Cancer Patients Undergoing Radiation Therapy
NCT07467083Head and Neck Cancer
West China Hospital
Phase 3
170
Chengdu
2026-03-15
Recruiting
A Study to Investigate the Efficacy and Safety of Frexalimab Versus Tacrolimus in Adults Undergoing Kidney Transplantation
NCT07412470Kidney Transplant Rejection
Sanofi
Phase 2/3
526
Beijing, Chengdu, Guangzhou, Hangzhou, Jinan, Nanchang, Nanning, Shanghai
2026-03-13
Active, closed
An Extension Study to Investigate the Long-term Safety and Tolerability of Itepekimab in Adult Participants With Inadequately Controlled Chronic Rhinosinusitis With Nasal Polyps
NCT07424144Chronic Rhinosinusitis With Nasal Polyps
Sanofi
Phase 3
59
Baotou, Beijing, Chengdu, Jingzhou, Shenyang, Taiyuan
2026-03-12
Recruiting
A Phase III Study of Deuremidevir Hydrobromide for the Treatment of RSV Infection in Infants and Young Children
NCT07402512Respiratory Syncytial Virus Infection
Simcere Pharmaceutical Co., Ltd
Phase 3
498
Xiamen, Changsha, Chengdu, Hangzhou
2026-03-11
Recruiting
A Multicenter, Non-interventional, Descriptive Study to Assess Assay Concordance of HER2 IHC Testing in Chinese Pan-tumor Patients
NCT07404202Pan-tumor(NSCLC, GYN Cancers, BTC and UC)
AstraZeneca
Observational
2,100
Beijing, Changsha, Chengdu, Guangzhou, Haerbin, Jinan, Nantong, Shanghai
2026-03-06
Active, closed
Analysis of Optimal Treatment Sequencing of Surufatinib and Somatostatin Analogs in Neuroendocrine Tumors: A Retrospective Cohort Study
NCT07534371Neuroendocrine Tumors
West China Hospital
Observational
500
Chengdu
2026-03-06
Not yet open
Safety and Efficacy Evaluation of an Extensively Hydrolyzed Formula in Infants With Cow's Milk Protein Allergy (CMPA)
NCT07484035Cow's Milk Protein Allergy (CMPA)
Heilongjiang Feihe Dairy Co. Ltd.
Not applicable
124
Beijing, Foshan, Zhuhai, Xiangtan, Wuxi, Chengdu
2026-03-05
Recruiting
A Study to Evaluate the Efficacy and Safety of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer
NCT07284849CRC (Colorectal Cancer)
Incyte Corporation
Phase 3
700
Beijing, Changsha, Chengdu, Chongqing, Foshan, Fuzhou, Guangzhou, Hangzhou
2026-03-05
Recruiting
CHOICE:Decision Factor of EGFR-TKI in Chinese IV NSCLC
NCT07413757Non-Small Cell Lung Cancer
AstraZeneca
Observational
590
Chengdu
2026-03-02
Recruiting
H101 Plus TACE for r/m HNSCC
NCT07398664Head and Neck Squamous Cell Carcinoma, Oncolytic Virus, TACE
West China Hospital
Phase 2
20
Chengdu
2026-03-02
Not yet open
Predicting Hypothermia in Gynecological Laparoscopic Surgery Using Machine Learning
NCT07353528Laparoscopic Surgery, Intraoperative Hypothermia, Gynecological Surgery
Chengdu Jinjiang Maternity and Child Health Hospital
Observational
1,000
Chengdu
2026-03-01
Recruiting
Clinical Trial of an Anti-Fog Drainage Device for Endoscopic Endonasal Sellar Region Tumor Surgery
NCT07316101Pituitary Adenoma, Craniopharyngioma
West China Hospital
Not applicable
20
Chengdu
2026-03-01
Recruiting
A Phase II Study of Sintilimab Combined With Ipilimumab N01, Cetuximab and Dabrafenib in Patients With Microsatellite-Stable, BRAF V600E-Mutated Metastatic Colorectal Cancer
NCT07506109BRAF V600E, Colorectal Cancer, Sintilimab, MSS (Microsatellite Stable)
Tianjin Medical University Cancer Institute and Hospital
Phase 2
49
Beijing, Wuhan, Chengdu, Tianjin
2026-03-01
Recruiting
Safety and Efficacy of Transarterial ICG Fluorescence-Guided Laparoscopic Anatomical Liver Resection
NCT07295275Liver Cancer
West China Hospital
Observational
200
Beijing, Xuzhou, Chengdu
2026-03-01
By invitation
Influencing Factors and Mechanisms of Capsular Contracture After Prosthesis Reconstruction in Patients With Breast Cancer
NCT07419971Breast Cancer Females, Breast Reconstruction
West China Hospital
Observational
300
Chengdu
2026-03-01
Recruiting
Topical Periplaneta Americana-Derived Meilian Fuxin Liquid for Radiation Dermatitis
NCT07353671Radiation-induced Dermatitis
West China Hospital
Phase 2/3
60
Chengdu
2026-03-01
Recruiting
To Evaluate the Tolerability and Pharmacokinetics of TQB3142 for Injection in Patients With Advanced Malignant Tumors
NCT07338838Advanced Malignant Tumors
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 1
66
Guangzhou, Zhengzhou, Chengdu, Luzhou, Hangzhou
2026-02-26
Recruiting
A Phase II Trial of LM103 for Adjuvant Treatment in Patients With Non-small Cell Lung Cancer
NCT07444437Non-Small Cell Lung Cancer
Suzhou BlueHorse Therapeutics Co., Ltd.
Phase 2
45
Guangzhou, Zhengzhou, Chengdu
2026-02-26
Recruiting
A Study to Test if Tenecteplase Helps People to Recover From an Acute Stroke When Given More Than 4.5 Hours After the Person Was Last Seen Well
NCT07361302Acute Ischemic Stroke
Boehringer Ingelheim
Phase 3
1,325
Anyang, Baoji, Baotou, Beijing, Cangzhou, Changchun, Changsha, Chengdu
2026-02-17
Recruiting
A Study to Find Out if BI 764198 Helps Adults and Adolescents With a Kidney Condition Called Focal Segmental Glomerulosclerosis (FSGS)
NCT07220083Focal Segmental Glomerulosclerosis
Boehringer Ingelheim
Phase 3
286
Baotou, Beijing, Changchun, Changsha, Chengdu, Guangzhou, Hangzhou, Lanzhou
2026-02-16
Recruiting
A Clinical Trial of Flonoltinib Maleate for Intermediate or High-Risk Myelofibrosis
NCT07317700MF
Chengdu Zenitar Biomedical Technology Co., Ltd
Phase 3
105
Chengdu, Tianjin
2026-02-13
Recruiting
Modified LCH-III Regimen With or Without Luvometinib for Multisystem Pediatric Langerhans Cell Histiocytosis
NCT07431060Langerhans Cell Histiocytosis (LCH)
West China Second University Hospital
Not applicable
120
Chengdu, Guiyang, Hefei, Jiangxi, Kunming, Nanning, Ürümqi, Xi'an
2026-02-13
Recruiting
Gelaspan vs Crystalloid Therapy in Sepsis
NCT07172451Sepsis, Intra-Abdominal Infections
Shanghai Zhongshan Hospital
Phase 4
318
Guangzhou, Nanjing, Suzhou, Xuzhou, Shanghai, Chengdu, Tianjing, Hangzhou
2026-02-13
Recruiting
MRG003 Plus HX008 as First-Line Treatment for EGFR-Positive Locally Advanced or Metastatic Penile Squamous Cell Carcinoma
NCT07054307Penile Cancer
Jiyan Liu
Phase 1
10
Chengdu
2026-02-12
Recruiting
A Study of Eloralintide (LY3841136) in Participants With Obstructive Sleep Apnea and Obesity or Overweight
NCT07369011Sleep Apnea, Obstructive, Obesity, Overweight
Eli Lilly and Company
Phase 3
800
Beijing, Changchun, Changsha, Chengdu, Chongqing, Guangzhou, Hefei, Kunming
2026-02-10
Recruiting
A Study of Eloralintide (LY3841136) in Participants With Persistent Obesity Who Are Treated With a Weekly Incretin
NCT07392190Overweight, Obesity
Eli Lilly and Company
Phase 3
900
Changchun, Changsha, Chengdu, Chongqing, Guangzhou, Guiyang, Hefei, Huzhou
2026-02-10
Recruiting
A Study of Brenipatide in Adult Participants With Schizophrenia
NCT07410507Schizophrenia
Eli Lilly and Company
Phase 2
450
Changsha, Chengdu, Hangzhou, Suzhou, Tianjin, Wuhu, Xi'an, Zhumadian
2026-02-10
Not yet open
Effectiveness and Safety of a Type A Dissection Total Endovascular Reconstruction System in Promoting Favorable Distal Aortic Remodeling
NCT07402252Residual Dissection After Repair for Type A Aortic Dissection
West China Hospital
Not applicable
198
Chengdu
2026-02-09
Recruiting
A Study of Brenipatide in Adult Participants With Major Depressive Disorder
NCT07412756Depressive Disorder, Major
Eli Lilly and Company
Phase 3
1,000
Beijing, Changsha, Chengdu, Guangzhou, Haidian District, Hefei, Huzhou, Jining
2026-02-09
Recruiting
A Study of Eloralintide (LY3841136) in Participants With Obesity, or Overweight Without Type 2 Diabetes
NCT07321886Obesity, Overweight
Eli Lilly and Company
Phase 3
1,980
Beijing, Chengdu, Guangzhou, Hefei, Jinan, Luoyang Shi, Nanchang, Nanjing
2026-02-06
Recruiting
A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma
NCT07258511Multiple Myeloma
Janssen Research & Development, LLC
Phase 3
400
Beijing, Chengdu, Guangzhou, Hangzhou, Nanjing, Nanning, Shanghai, Wenzhou
2026-02-04
Recruiting
Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2
NCT07431281Gastric Cancer, Gastroesophageal Junction Adenocarcinoma, Esophageal Cancer
AstraZeneca
Phase 3
2,130
Beijing, Changde, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Harbin
2026-02-03
Recruiting
A Phase II Clinical Study Evaluating of ZL-82 Tablets in Atopic Dermatitis
NCT07193589Atopic Dermatitis
Chengdu Zenitar Biomedical Technology Co., Ltd
Phase 2
111
Chengdu
2026-02-03
By invitation
Neurofeedback Training of Anterior Insula Activity Based on Unidimensional vs. Multidimensional Interoceptive Regulation Strategies
NCT07416370Healthy
University of Electronic Science and Technology of China
Not applicable
60
Chengdu
2026-02-02
Not yet open
Perioperative Ivonescimab Plus S-1 and Oxaliplatin (SOX) for Locally Advanced Gastric or GEJ Adenocarcinoma
NCT07374250Gastric Cancer, RCT
Sichuan University
Phase 2
154
Chengdu
2026-02-01
Not yet open
Dexamethasone Regimens for BPD Prevention in Preterm Infants
NCT07052201Infant, Premature, Bronchopulmonary Dysplasia (BPD)
The Children's Hospital of Zhejiang University School of Medicine
Phase 3
970
Hangzhou, Chengdu, Chongqing, Guangdong, Guangxi, Guiyang, Guizhou, Jilin City
2026-02-01
Recruiting
A Multicenter Clinical Study of Combined Therapy for Unresectable Hepatocellular Carcinoma
NCT07482059Unresectable Hepatocellular Carcinoma
West China Hospital
Phase 1/2
33
Chengdu
2026-02
Recruiting
Structured Active Follow-up in Postoperative Management of Thyroid
NCT07589660Patients After Thyroid Surgery
Yu Feng
Not applicable
244
Chengdu
2026-01-31
Recruiting
Prognosis of Primary Aldosteronism: A Prospective Cohort Study
NCT07378176Primary Aldosteronism
Xinjiang Medical University
Observational
5,000
Chengdu, Ürümqi
2026-01-30
Recruiting
A Clinical Study of Gocatamig (MK-6070) and Infinatamab Deruxtecan (MK-2400) in People With Small Cell Lung Cancer (MK-6070-003)
NCT07227597Small Cell Lung Cancer Extensive Stage
Merck Sharp & Dohme LLC
Phase 1/2
170
Beijing, Fuzhou, Guangzhou, Jiangmen, Nanchang, Shanghai, Chengdu, Hangzhou
2026-01-29
Recruiting
This is a Multi-Center Study of IBI3026 in Participants With Locally Advanced, Unresectable or Metastatic Solid Tumors
NCT07327632Solid Tumor
Innovent Biologics Technology Limited (Shanghai R&D Center)
Phase EARLY_PHASE1
300
Chengdu
2026-01-29
Recruiting
Continuous vs. Intermittent Rt-fMRI Neurofeedback Training of the Anterior Insula
NCT07389486Healthy
University of Electronic Science and Technology of China
Not applicable
90
Chengdu
2026-01-28
Recruiting
Phase 3b Study in Patients With Severe Asthma Treated With Tezepelumab
NCT07363642Severe Asthma
AstraZeneca
Phase 3
400
Beijing, Binzhou, Changsha, Chengdu, Chongqing, Deyang, Fuzhou, Guangzhou
2026-01-28
Recruiting
A Trial to Learn How Safe AZD9750 is and How Well it Works in People With Metastatic Prostate Cancer When Given With or Without Other Anticancer Drugs
NCT07336446Prostate Cancer
AstraZeneca
Phase 1/2
300
Chengdu
2026-01-27
Active, closed
Time-Restricted Eating for Weight-Loss Maintenance
NCT07163455Overweight or Obese Adults
Harbin Medical University
Not applicable
500
Beijing, Chongqing, Shenzhen, Harbin, Xi'an, Qingdao, Weifang, Chengdu
2026-01-26
Recruiting
Oxytocin's Effects on Emotional Processing and Its Acting Routes
NCT07425938Healthy Adult Male
University of Electronic Science and Technology of China
Not applicable
120
Chengdu
2026-01-24
Recruiting
A Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of TQB3122 Capsules in Subjects With Advanced Malignant Tumors
NCT07269145Advanced Cancer
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 1
86
Beijing, Fuzhou, Meizhou, Shanghai, Chengdu
2026-01-22
Recruiting
A Study to Evaluate the Effectiveness and Safety of Inavolisib in Participants With Endocrine-resistant, PIK3CA-mutated, Hormone Receptor-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer
NCT07347600Locally Advanced Breast Cancer, Metastatic Breast Cancer
Hoffmann-La Roche
Observational
500
Xiamen, Lanzhou, Changchun, Wenzhou, Beijing, Chengdu, Chongqing, Guangzhou
2026-01-21
Recruiting
Efficacy and Safety of Dalpiciclib Combined With Endocrine Adjuvant Therapy for Early HR +/HER2- Breast Cancer: a Multicenter, Prospective Clinical Study
NCT07581834Breast Diseases, Breast Neoplasms, Dalpiciclib, Endocrine Breast Diseases
Fujian Cancer Hospital
Phase 2
2,000
Fuzhou, Chengdu
2026-01-21
Recruiting
The Efficacy and Safety of Inpegsomatropin Injection in Children With Short Stature Born Small for Gestational Age
NCT07309562Small for Gestational Age
Xiamen Amoytop Biotech Co., Ltd.
Phase 3
141
Beijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Haikou
2026-01-20
Active, closed
A Study of JNJ-95597528 in Participants With Moderate to Severe Atopic Dermatitis
NCT07230860Dermatitis, Atopic
Janssen Research & Development, LLC
Phase 2
189
Beijing, Changsha, Chengde, Chengdu, Guangzhou, Sanmenxia, Wuxi, Xi'an
2026-01-20
Recruiting
A Phase II Study to Evaluate the Efficacy and Safety of D-2570 in Subjects With Active Psoriatic Arthritis
NCT07315061PsA (Psoriatic Arthritis)
InventisBio Co., Ltd
Phase 2
222
Chengdu
2026-01-16
Recruiting
Real-time Neurofeedback Training of the Medial Prefrontal Cortex Based on Imagined Social Support
NCT07364084Healthy, Neurofeedback
University of Electronic Science and Technology of China
Not applicable
60
Chengdu
2026-01-16
Recruiting
Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD Mutations
NCT07195695Non-small Cell Lung Cancer
Boehringer Ingelheim
Phase 3
400
Beijing, Changchun, Changsha, Chengdu, Guangzhou, Hangzhou, Harbin, Jinan
2026-01-16
Recruiting
A Study to Evaluate the Efficacy and Safety of JNJ-88545223 for the Treatment of Participants With Active Psoriatic Arthritis
NCT07321873Arthritis, Psoriatic
Janssen Research & Development, LLC
Phase 2
240
Beijing, Changsha, Changzhou, Chengdu, Chongqing, Hangzhou, Ningbo, Shanghai
2026-01-15
Not yet open
Phase Ib/IIa Clinical Trial of SIBP-A16 Injection in Premature Infants and Full-term Infants
NCT07363837Respiratory Syncytial Virus (RSV)
Shanghai Institute Of Biological Products
Phase 1/2
36
Chengdu
2026-01-15
Recruiting
Non-inferiority Study of Frexalimab Subcutaneous Administration Compared to Intravenous Administration in Adult Participants With Multiple Sclerosis
NCT07325292Multiple Sclerosis
Sanofi
Phase 3
160
Beijing, Chengdu, Jiazhuang
2026-01-14
Recruiting
A Study of HRS-1301 Tablets in Healthy Subjects and Those With Impaired Kidney Function
NCT07322016Hyperlipidemias
Shandong Suncadia Medicine Co., Ltd.
Phase 1
36
Chengdu
2026-01-13
Recruiting
Efficacy and Safety of Lusutrombopag After Allogeneic Hematopoietic Stem Cell Transplantation
NCT07483385Patients With Hematologic Disorders After Allogeneic Hematopoietic Stem Cell Transplantation, Hematologic Disorders
The General Hospital of Western Theater Command
Not applicable
45
Chengdu
2026-01-13
Not yet open
Spirulina Derivative for Radiation Esophagitis
NCT07324018Radiation-induced Esophagitis
West China Hospital
Phase 2
70
Chengdu
2026-01-12
Not yet open
Nanocrystalline Megestrol Acetate for Cachectic Stage Locally Advanced Hepatocellular Carcinoma
NCT07356037Cachexia, Hepatocellular Carcinoma
Changchun GeneScience Pharmaceutical Co., Ltd.
Phase 3
68
Chengdu
2026-01-10
Recruiting
A Research Study on How Well Cagrilintide and CagriSema Work in Children and Adolescents With Excess Body Weight
NCT07253285Overweight, Obesity
Novo Nordisk A/S
Phase 3
460
Beijing, Zhengzhou, Wuhan, Changchun, Jinan, Shanghai, Chengdu
2026-01-08
Rows per page Showing 201–300 of 1291
Previous 1 2 3 4 5 Next
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 24 September 2026. https://priyalifescience.com/clinical-trials-china/city/chengdu?page=3

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,052 studies in total at the last sync on 22 Sep 2026, 11:10 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 1,291 of those studies with a site in Chengdu.

How many clinical trials are recruiting in Chengdu?

732 of the 1,291 studies on this page are recruiting new participants as of the 22 Sep 2026, 11:10 UTC sync. A further 177 have not yet opened recruitment, 354 are active but closed to new participants, and 28 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.